Pentravan | 2021 Assessment of the effect of structural modification of Ibuprofen on the penetration of Ibuprofen from Pentravan® (Semisolid) formulation using human skin and a transdermal diffusion test model Ossowicz-Rupniewska P, Nowak A, Klebeko J, Janus E, Duchnik W, Adamiak-Giera U, Kucharski L, Prowans P, Petriczko J, Czapla N, Bargiel P, Markowska M, Klimowicz A Materials, 14(22), 6808-6826 The effect of Pentravan® on skin permeability was examined for unmodified ibuprofen (IBU) and ion pairs of ibuprofen with new L-valine alkyl esters. The resulting Pentravan-based creams with ibuprofen in the form of an ionic pair represent a potential alternative to other forms of the drug-containing analgesics administered transdermally. Read more SEE PRODUCT
Pentravan | 2021 Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan® for transdermal and transmucosal application Polonini HC, Ferreira AO, Dijkers E International Journal of Pharmaceutical Compounding, 25(5), 422-426 In this work, the compatibility of Pentravan and three active pharmaceutical ingredients was determined: gestrinone, a steroidal substance for vaginal use, and nimesulide and piroxicam, two nonsteroidal anti-inflammatory drugs used for topical and vaginal application. This article shows an excellent beyond-use date of 180 days when stored at room temperature. Read more SEE PRODUCT
Pentravan | 2021 Compatibility of different formulations in Pentravan® and Pentravan® Plus for transdermal drug delivery Polonini HC, Taylor S, Zander C Scientia Pharmaceutica, 89(4), 51 In this study, the stability in Pentravan®/Plus of danazol, metformin HCl, and resveratrol, as well as metformin HCl, resveratrol, and Vitamin D3 in combinations at bracketed high/low concentrations, were evaluated over a period of 6 months. All formulations presented a beyond-use date of at least 6 months. Read more SEE PRODUCT
Phytobase Cream | 2021 Stability of Fagron’s phytobase cream compounded with various hormones Wynn T, Taylor S, Zander C International Journal of Pharmaceutical Compounding, 25(2), 156-162 The objective of this study was to evaluate the stability of estrone (0.1-1%), estradiol (0.05-2%), estriol (0.05-2%), progesterone ( 0.1-20%), testosterone (0.1-20%), combination (estradiol 0.05%, estriol 0.05%, progesterone 0.5%), and combination (estradiol 2%, estriol 1%, progesterone 20%). The beyond-use date was 180 days in all samples except estrone (150 days). Read more SEE PRODUCT
ImmunoFormulation | 2020 ImmunoFormulation for COVID-19 Diaz M Encyclopedia, online The study describes the cases of four COVID-19 patients that used a combination of Imuno TF®, Miodesin®, and SiliciuMax® for improvement of their symptoms. The four showed improvement in general symptoms after treatment, representing a good starting point to further investigate this possible add-on therapy in controlled clinical studies. Read more
ImmunoFormulation | 2020 Evolution of COVID-19 patients treated with ImmunoFormulation, a combination of nutraceuticals to reduce symptomatology and improve prognosis: a multi-centered, retrospective cohort study Diaz Hernandez M, Urrea J, Bascoy L medRxiv, online The study followed the progression of COVID-19 in patients treated with ImmunoFormulation (IF) versus untreated patients. Throughout the observational period, 90% of patients recovered in the IF cohort (47.4% in the Control cohort). Symptom duration was shorter in the IF cohort, especially for fever, dry cough, dyspnoea, diarrhoea, and weakness. Read more
ImmunoFormulation | 2020 Postulated adjuvant therapeutic strategies for COVID-19 Ferreira AO, Polonini HC, Dijkers E Journal of Personalized Medicine, 10(3), 80-113 This review gives the scientific background on the hypothesis that Imuno TF®, Miodesin®, and SiliciuMax® can act in synergy in the prevention and improvement of COVID-19-associated symptoms. Read more
ImunoTF | 2020 Immunoregulatory effects of Imuno TF®(transfer factors) on Th1/Th2/Th17/Treg cytokines Rocha Oliveira C, Paula Vieira R, Ferreira AO, de Souza SG, Polonini HC bioRxiv, online The study evaluated the effect of Imuno TF® on the immune system. Th1 cytokines were upregulated, while decreasing Th2 cytokines. mRNA and anti-inflammatory cytokine IL-10 levels increased, whereas mRNA and pro-inflammatory cytokines IL-6 and TNF-α were reduced. Finally, it reversed IL-17 hypersecretion and did not alter IL-35 secretion. Read more SEE PRODUCT
ImunoTF | 2020 Effect of sublingual isolated transfer factors in a case of therapy resistant periungual warts Nascimento e Silva M, Gonçalves K Journal of Dermatology Research and Therapy, 6(2), 89-91 This case study describes a patient with periungual warts (PW) resistant to a range of standard treatments. His clinical condition dramatically improved after use of isolated transfer factors (TF). As shown in this case, TF could be a possible effective alternative to treat therapy-resistant PW. Read more SEE PRODUCT
Syrspend SF | 2020 Content uniformity of extemporaneous compounded suspensions Dijkers E, Polonini HC, Ferreira AO European Journal of Hospital Pharmacy, 27(Suppl1), A37.2-A38 The study investigated the content uniformity of a wide range of different active pharmaceutical ingredients (APIs) in SyrSpend SF, and compared with what is known for the content uniformity of extemporaneous prepared capsules. Compounded oral liquids in SyrSpend SF showed little content variation, and were well within the criteria defined. Read more SEE PRODUCT